| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.974 | 6.418 | 2.861 | 19.986 | 20.460 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 7.974 | 6.418 | 2.861 | 20.137 | 20.479 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 7.594 | 5.942 | 2.628 | 22.609 | 21.340 | 0 | 0 | 0 | 40 | 40 |
| Gross Profit/Loss - EUR | 380 | 477 | 233 | -2.471 | -861 | 0 | 0 | 0 | -40 | -40 |
| Net Profit/Loss - EUR | 140 | 284 | 147 | -3.076 | -1.475 | 0 | 0 | 0 | -40 | -40 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Dovirox Com S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 13.420 | 13.316 | 14.549 | 29.994 | 2.155 | 1.509 | 975 | 821 | 819 | 814 |
| Inventories | 13.049 | 13.083 | 13.940 | 27.916 | 853 | 837 | 819 | 821 | 819 | 814 |
| Receivables | 277 | 212 | 226 | 1.958 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 93 | 20 | 384 | 119 | 1.301 | 672 | 156 | 0 | 0 | 0 |
| Shareholders Funds | -14.832 | -14.397 | -14.006 | -16.825 | -17.974 | -17.633 | -17.242 | -17.295 | -17.283 | -17.227 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 28.251 | 27.712 | 28.555 | 46.818 | 20.128 | 19.142 | 18.217 | 18.116 | 18.102 | 18.041 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4781 - 4781" | |||||||||
| CAEN Financial Year |
4711
|
|||||||||
Comments - Dovirox Com S.r.l.